Objective: To determine if adequate syringe coverage --"one shot for one syringe"--among syringe exchange program (SEP) clients is associated with injection-related HIV risk behaviors and syringe disposal.
Design: HIV risk assessments with 1577 injection drug users (IDUs) recruited from 24 SEPs in California between 2001 and 2003. Individual syringe coverage was calculated as a proportion of syringes retained from SEP visits to total number of injections in the last 30 days.
Results: Participants were divided into four groups based on syringe coverage: <50%, 50-99%, 100-149%, and 150% or more. In multivariate logistic regression, SEP clients with less than 50% syringe coverage had significantly higher odds of reporting receptive syringe sharing in the last 30 days (adjusted odds ratio [AOR]=2.3; 95% confidence interval [CI]=1.4, 3.6) and those with 150% or more coverage had lower odds of reporting receptive syringe sharing (AOR=0.5; 95%CI=0.3, 0.8) as compared to SEP clients with adequate syringe coverage of 100-149%. Similar associations were observed for other main outcomes of distributive syringe sharing and syringe re-use. No differences in safe syringe disposal were observed by syringe coverage.
Conclusions: Individual syringe coverage is strongly associated with safer injection behaviors without impacting syringe disposal among SEP clients. Syringe coverage is a useful measure for determining if IDUs are obtaining sufficient syringes to lower HIV risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2562866 | PMC |
| http://dx.doi.org/10.1016/j.drugalcdep.2006.12.035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progress and challenges in the elimination of hepatitis C among people who inject drugs in Germany: results of a pilot study for a national monitoring system, 10 years after the first data collection.
Harm Reduct J
December 2024
Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Background: People who inject drugs (PWID) are at high risk of blood-borne infections, and injection drug use contributes significantly to hepatitis C virus (HCV) transmission. The WHO has therefore set targets of reducing HCV incidence and prevalence among PWID and increasing treatment coverage to eliminate HCV by 2030. The DRUCK study (2011-2014) found high HCV prevalence and low treatment coverage among PWID in Germany.
View Article and Find Full Text PDFEstimates of Potential Demand for Measles and Rubella Microarray Patches.
Vaccines (Basel)
September 2024
The U.S. Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA.
Article Synopsis
- Global measles vaccine coverage has been stuck at around 85% for over ten years, and a new microarray patch (MR-MAP) could help increase this by simplifying the vaccination process.
- Clinical trials show that MR-MAPs are safe and effective for infants, similar to traditional syringe vaccinations.
- A demand estimation tool was developed using data from 180 WHO countries, predicting varying demand for MR-MAPs based on different vaccination strategies, with estimates ranging from 137 million to 2.587 billion doses needed in different scenarios by 2025-2034.
An Application of an Initial Full Value of Vaccine Assessment Methodology to Measles-Rubella MAPs for Use in Low- and Middle-Income Countries.
Vaccines (Basel)
September 2024
UNICEF, 2100 Copenhagen, Denmark.
Article Synopsis
- Measles and rubella micro-array patches (MR-MAPs) are innovative alternatives to traditional needle and syringe vaccines, offering single-dose convenience, easier handling, and better temperature stability.
- An initial full value vaccine assessment (iFVVA) evaluated their potential impact, finding that widespread use of MR-MAPs could prevent millions of measles cases, deaths, and years lost to disability by reaching an additional 80 million children over the next decade.
- The assessment also emphasized the need for financial investment in manufacturing and clinical studies, while showing that MR-MAPs have the potential to be cost-effective for routine immunization in many low- and middle-income countries, depending on pricing and coverage uncertainties.*
Modeling the impact of a supervised consumption site on HIV and HCV transmission among people who inject drugs in three counties in California, USA.
Int J Drug Policy
October 2024
University of California San Diego, CA, USA; University of Bristol, Bristol, UK.
Background: Supervised consumption sites (SCS) have been shown to reduce receptive syringe sharing among people who inject drugs (PWID) in the United States and elsewhere, which can prevent HIV and hepatitis C virus (HCV) transmission. PWID are at risk of disease transmission and may benefit from SCS, however legislation has yet to support their implementation. This study aims to determine the potential impact of SCS implementation on HIV and HCV incidence among PWID in three California counties.
View Article and Find Full Text PDFHepatitis B and hepatitis C are leading causes of cirrhosis and liver cancer and caused 1.3 million deaths worldwide in 2022. Hepatitis B is preventable with vaccination, and hepatitis C is curable with direct-acting antivirals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!